Aortech Share Discussion Threads

[davisc5] 27/11/2019 13:47

Wow, didn't expect it that quick!

[someuwin] 27/11/2019 13:46

Yes £13m does seem absurdly cheap for a serious medical device company.

[alanrussell] 27/11/2019 13:34

Even with the recent run and today's jump that MCAP is just silly. Have added.

[someuwin] 27/11/2019 13:34

This has come completely out of the blue and now makes AOR very cheap on its existing Elast-Eon line. With all the blue sky potential of the new products on top too.

[davisc5] 27/11/2019 13:29

Nice RNS, just what was needed, hope we can push into triple figures.

[ny boy] 27/11/2019 13:25

A nice slow climb to 400p now, tucked mine away, after adding on earlier weakness
Meanwhile accumulating more (FOXT) & (FUL) for recovery.

[semper vigilans] 27/11/2019 13:23

Well done AOR!

[someuwin] 27/11/2019 13:23

This looks BIG.

[someuwin] 27/11/2019 13:20

AorTech International PLC

27 November 2019

AorTech International plc

("AorTech", the "Company" or the "Group")

New Licence Agreement

AorTech International plc (AIM: AOR.L), the licensor of the world's leading long-term implantable biostable polymer (Elast-Eon(TM) ) and developer of medical devices enabled by Elast-Eon(TM) , is pleased to announce that it has entered into an IP licence agreement with Medibrane Limited ("Medibrane") allowing the use of Elast-Eon(TM) for encapsulation of medical devices.

Medibrane is a leading Israeli designer, developer, and manufacturer of customised biomaterial polymeric coverings and coatings of scaffolds-based applications intended for neurology, cardiovascular, structural heart and urology, as well as for gastroenterology, biliary and respiratory devices.

The licence agreement anticipates Medibrane incorporating Elast-Eon(TM) into medical devices at the design stage and allows Medibrane to further sub-license Elast-Eon(TM) to its customers.

Elad Einav, CEO of Medibrane, said: "We have already trialled the Elast-Eon(TM) material for some applications and found it to have a number of benefits over other polymers with regard to manufacturing process stability as well as cohesiveness. This coupled with the world class biocompatible and biostable properties of Elast-Eon(TM) should allow us to help grow the number of uses for Elast-Eon(TM) in medical devices."

Bill Brown, Chairman of AorTech, said: "The AorTech team has been very impressed with Medibrane's technical capabilities and look forward to a long and successful partnership with them. We are delighted to be working with a commercially focused business such as Medibrane to help promote a greater number of Elast-Eon(TM) enabled medical devices."

[greedy rooster] 27/11/2019 13:19

New licence agreement.

[cocker] 26/11/2019 18:17

Yes. Unfortunately paid more than what I sold them for, but believe perhaps re rating due if news is upbeat. Timing with these sort of stocks always difficult but having said that, the rise has been steady over the last few weeks and I added my last 5k the other day at 77p. Average now around 60p so we will see if I end up with egg on my face or not so the case maybe.

[cocker] 26/11/2019 15:27

Anyone had a firm date yet other than late November for results. Get a bit twitchy as well as soaking wet today

[langland] 25/11/2019 08:31

Active Capital liquidated itself.

[someuwin] 25/11/2019 08:26

Again, very little stock offered for sale.

With Results / project update expected this week, it could get very interesting.

[redbraces] 24/11/2019 20:18

I remember back in the 1990's Bill Brown ran the Aim trust.
Companies included, AOR and BATM, both did well.

However, I think when realism, struck home i.e.
the dot com crash, they all failed. But, I believe in
Bill Brown. He is an accountant and would not have stuck
with AOR, if he didn't think it was a bad investment.

[bones] 24/11/2019 19:39

kibtf, thanks for the eyewitness view!

I am not sure what you mean by the liquidation though. That has never happened to AorTech.

[kibtf] 24/11/2019 15:38

Bones
I well remember that period. One of the biggest shareholders/supporters was Active Capital Investment Trust, run by one Bill Brown, which I think owned 20+% of AOR!. One of my very worst investments by the time it had been liquidated. This is the classic case of a share that owes me- which probabily doesn't bode well...

[langland] 23/11/2019 20:45

Agree NYB. Should get to well over a quid on the next run.

[ny boy] 23/11/2019 20:15

Looks primed to breakout and go on an extended run, will keep holding.

[bones] 23/11/2019 14:54

Thanks Landy.

I have completed an excel spreadsheet that chronologically records every share issue ever done by Aortech since it floated in 1997. Maybe it is of historical interest but it does shine a light on the explosion of activity, hopes and hubris that took place in the early years with the share price (adjusted for the 2003 1-for-10 consolidation) over 1,000p at the height of the tech boom (March 2000). Maximum market cap at the time seems to have been around £300M. NB Today’s M Cap < £12M.

From the initial £3.6M raised on flotation in 1997 (around 20% of shares in issue), a further £80M (yes, Eighty Million pounds) was raised. Most of this was before 2003. There was even a £64M proposed share financing in 2001 that was shouted down by investors and replaced by a much cheaper £20M one.

A very long period of stasis and lawsuits followed until 2018 when the latest strategy was unveiled and £2.7M was raised.

The fact that the most recent raise was dwarfed in value by what had gone before in the distant past speaks of the difference in market conditions and the difference between what can happen when a stock is hot property during a bull market with an enthusiastic following compared to now when a stock is under the radar, ignored and of no interest to general investors in a small cap bear market. Yet, over 60% of the current share count of 14.7M was issued during that last raise in 2018. Such is the penal price of raising money when under pressure.

We can only fantasize about what valuation would be placed on AOR if the market conditions ever turn properly bullish and further solid progress toward manufacturing and approving the latest devices is achieved.

If anyone would like a copy of the analysis, send me a PM.

[landy90] 22/11/2019 17:38

Bones, a very interesting analysis. A good lesson in using paper when valuations are high.